The non-motor symptoms in Parkinsons’s disease patients treated with STN DBS: the follow up study
Objective: The aim of the study was to follow-up the effect of STN DBS on motor and non-motor symptoms in aPD. Background: A comprehensive assessment…Tear tumor necrosis factor-alpha levels in patients with Parkinson’s disease: The effect of deep brain stimulation
Objective: To evaluate tear tumor necrosis factor-alpha (TNF-α) levels in samples of two Parkinson’s disease (PD) patients treated with subthalamic nucleus (STN) deep brain stimulation…An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia
Objective: To establish a minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score change using data from randomized, double-blind, placebo…An Unusual Cause of Rhabdomyolysis in Parkinson’s disease
Objective: To describe an unusual cause of rhabdomyolysis in patient with advanced Parkinson’s disease (PD) treated with levodopa. Background: Rhabdomyolysis is a serious and life-threatening…Association analysis of single nucleotide polymorphisms near the DYT3 locus to dystonic symptoms in X-linked dystonia-parkinsonism
Objective: We aimed to elucidatewhether single nucleotide polymorphisms within the XDP locus affect the phenotypic expression of XDP. Background: X-linked Dystonia-Parkinsonism (XDP, DYT3, Lubag Disease,…Rice bran extract against animal model of Huntington’s disease: Possible role of neurotransmitters
Objective: The present study has been designed to explore the effect of rice bran extract against 3-NP induced neurotoxicity in rats. Background: Huntington’s disease (HD)…A modified model for prediction of Huntington disease age of onset based on length of CAG repeat expansion
Objective: We aimed to search for a possibility to modify Langbehn et al. model (LanM) for prediction of Huntington disease (HD) age of onset based on length of CAG…Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD
Objective: To assess efficacy, safety, and tolerability of multiple doses of pridopidine in HD patients (pts) with signs of motor dysfunction. Background: Prior trials suggested…Metabolomic biomarkers strongly differentiate PD from healthy controls (HCs) in BioFIND study* specimens
Objective: To determine if metabolomic analysis - untargeted profiling of small-molecule (<1.5 kDalton) biochemical constituents - can yield useful diagnostic biomarkers of PD using CSF…Metabolic syndrome: Its link with motor function of Parkinson’s disease (PD)
Objective: To evaluate if metabolic risk factors can affect the motor function of PD patients Background: The etiology of PD remains unclear. It has been…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 155
- Next Page »